Las Vegas, NV -- (SBWIRE) -- 01/08/2013 -- Beststocksdaily is one of leading U.S. stock update providers to valued investors. Following are the notable volume leaders as reported by http://beststocksdaily.com/
Newcastle Investment Corp. (NYSE:NCT) is currently trading at $9.85, 2.55% higher. Newcastle Investment Corp. (Newcastle) is a real estate investment and finance company. Newcastle invests in, and actively manages, a portfolio of, real estate securities, loans, excess mortgage servicing rights (MSRs) and other real estate related assets. The Company segments include unlevered CDOs, which include unlevered investments in deconsolidated Newcastle CDO debt; unlevered excess MSRs; non-recourse other, which includes investments financed with other non-recourse debt; recourse, which includes investments and debt repurchases financed with recourse debt; unlevered other, which includes other unlevered investments, and corporate.
Can NCT Continues To Move Higher Back? Find Out Here http://beststocksdaily.com/p2/index.php?company=NCT
Peregrine Pharmaceuticals (NASDAQ:PPHM) is lower 3.71% to $2.34. Peregrine Pharmaceuticals, Inc. (Peregrine) is a biopharmaceutical company developing monoclonal antibodies for the treatment and diagnosis of cancer. The Company's pipeline of investigational monoclonal antibodies is based on two technology platforms, including PS-targeting antibodies and DNA/histone-targeting antibodies. Bavituximab is the Company's therapeutic PS-targeting antibody, which has demonstrated therapeutic potential and represents a new approach to treating cancer.
To Get complete technical analysis on PPHM go to http://beststocksdaily.com/p2/index.php?company=PPHM
Cell Therapeutics Inc (NASDAQ:CTIC) is higher 16.69% to $1.52. Cell Therapeutics, Inc. (CTI) develops, acquires and commercializes treatments for cancer. The Company’s research, development, acquisition and in-licensing activities concentrate on identifying and developing new ways to treat cancer. As of December 31, 2011, CTI focused its efforts on Pixuvri (pixantrone dimaleate) (Pixuvri), OPAXIO (paclitaxel poliglumex) (OPAXIO), tosedostat, brostallicin and bisplatinates. As of December 31, 2011, it developed Pixuvri, an anthracycline derivative for the treatment of hematologic malignancies and solid tumors.
Get Free Trend Analysis on CTIC Here http://beststocksdaily.com/p2/index.php?company=CTIC
Molycorp Inc (NYSE:MCP) among the losers and the stock fell 2.25% to $11.30. Molycorp, Inc. provides Rare Earths and Molybdenum products to companies. The Company's rare earth products comprise of bastnasite, cerium, europium, lanthanum, neodymium, praseodymium, yttrium, and other lanthanides.
To Get complete technical analysis on MCP go to http://beststocksdaily.com/p2/index.php?company=MCP
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) is higher 2.28% to $9.41. Arena Pharmaceuticals, Inc. (Arena) is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing oral drugs that target G protein-coupled receptors (GPCRs), in four therapeutic areas: cardiovascular, central nervous system, inflammatory and metabolic diseases. After completing various studies, analyses and other activities in response to the lorcaserin CRL, in December 2011, the Company resubmitted the lorcaserin NDA. Its wholly owned subsidiary, Arena Pharmaceuticals GmbH (Arena GmbH), has granted Eisai Inc., rights to commercialize lorcaserin in the United States and its territories and possessions, subject to the United States Food and Drug Administration (FDA) approval of the lorcaserin NDA.
Get Free Trend Analysis on ARNA Here http://beststocksdaily.com/p2/index.php?company=ARNA
Beststocksdaily’s team is engaged in providing valuable and updated news information on U.S. stocks on a regular basis. Beststocksdaily’s instant stock news on Major Gainers, small cap penny stocks and various other stocks, guides investors in making the wise stock market investments decision. To Get Instant updates in the inbox, readers are advised to sign up for free at Beststocksdaily.com.
The assembled information disseminated by beststocksdaily.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. beststocksdaily.com does expect that investors will buy and sell securities based on information assembled and presented in beststocksdaily.com. PLEASE always do your own due diligence, and consult your financial advisor.
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)